TBPH Q4 2019 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+87.4% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$71M-239.2% margin

Net Income

-$66M-222.4% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

+137.4%

Cash Flow

Operating Cash Flow

-$64M

Free Cash Flow

-$66M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$409M

Total Liabilities

$633M

Stockholders' Equity

-$224M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$16M	+87.4%
Gross Profit	$29M	$15M	+95.3%
Operating Income	-$71M	-$63M	-12.7%
Net Income	-$66M	-$50M	-30.7%

Revenue Segments

License

$10M34%

Co Promote Agreement

$10M34%

Collaborative Arrangement Revenue

$10M32%